467,383 Shares in Danaher Corporation $DHR Acquired by ABN Amro Investment Solutions

ABN Amro Investment Solutions acquired a new stake in Danaher Corporation (NYSE:DHR) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 467,383 shares of the conglomerate’s stock, valued at approximately $92,327,000. Danaher accounts for 1.8% of ABN Amro Investment Solutions’ holdings, making the stock its 10th largest holding. ABN Amro Investment Solutions owned approximately 0.07% of Danaher as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. MGO One Seven LLC raised its holdings in Danaher by 485.7% in the first quarter. MGO One Seven LLC now owns 25,098 shares of the conglomerate’s stock worth $5,145,000 after purchasing an additional 20,813 shares during the period. Chicago Capital LLC increased its position in shares of Danaher by 11.6% in the 2nd quarter. Chicago Capital LLC now owns 13,332 shares of the conglomerate’s stock valued at $2,634,000 after buying an additional 1,391 shares in the last quarter. UniSuper Management Pty Ltd raised its stake in Danaher by 1.6% during the 1st quarter. UniSuper Management Pty Ltd now owns 170,505 shares of the conglomerate’s stock worth $34,954,000 after buying an additional 2,667 shares during the period. Nvwm LLC raised its stake in Danaher by 20.4% during the 2nd quarter. Nvwm LLC now owns 7,093 shares of the conglomerate’s stock worth $1,401,000 after buying an additional 1,204 shares during the period. Finally, ASR Vermogensbeheer N.V. lifted its holdings in Danaher by 1.9% during the second quarter. ASR Vermogensbeheer N.V. now owns 322,924 shares of the conglomerate’s stock worth $63,787,000 after acquiring an additional 6,136 shares in the last quarter. 79.05% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. Robert W. Baird set a $247.00 price target on Danaher in a report on Wednesday, October 22nd. Redburn Partners set a $220.00 price objective on Danaher in a research report on Wednesday, October 8th. Deutsche Bank Aktiengesellschaft raised their target price on shares of Danaher from $235.00 to $250.00 and gave the stock a “buy” rating in a report on Wednesday, October 22nd. JPMorgan Chase & Co. lifted their price target on shares of Danaher from $260.00 to $270.00 and gave the company an “overweight” rating in a research note on Wednesday, October 22nd. Finally, Wall Street Zen cut shares of Danaher from a “buy” rating to a “hold” rating in a report on Monday. Eighteen equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Danaher presently has a consensus rating of “Moderate Buy” and an average target price of $243.39.

Insider Activity at Danaher

In related news, Director Teri List sold 2,778 shares of the firm’s stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the transaction, the director directly owned 20,751 shares of the company’s stock, valued at approximately $4,379,706.06. This trade represents a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Georgeann Couchara sold 5,174 shares of the business’s stock in a transaction on Monday, November 10th. The stock was sold at an average price of $210.42, for a total transaction of $1,088,713.08. Following the transaction, the senior vice president owned 2,625 shares in the company, valued at approximately $552,352.50. The trade was a 66.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 11.20% of the stock is owned by insiders.

Danaher Stock Up 1.8%

Shares of DHR stock opened at $219.60 on Thursday. The firm’s fifty day moving average price is $204.76 and its two-hundred day moving average price is $200.77. The company has a current ratio of 1.52, a quick ratio of 1.10 and a debt-to-equity ratio of 0.33. Danaher Corporation has a 1 year low of $171.00 and a 1 year high of $258.23. The firm has a market capitalization of $155.11 billion, a P/E ratio of 45.28, a PEG ratio of 3.28 and a beta of 0.81.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, October 21st. The conglomerate reported $1.89 EPS for the quarter, topping analysts’ consensus estimates of $1.72 by $0.17. The company had revenue of $6.05 billion during the quarter, compared to the consensus estimate of $6 billion. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The company’s quarterly revenue was up 4.4% on a year-over-year basis. During the same period in the prior year, the business posted $1.71 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, equities analysts predict that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, October 31st. Shareholders of record on Friday, September 26th were paid a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date was Friday, September 26th. Danaher’s dividend payout ratio (DPR) is currently 26.39%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.